ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4217-Benowa-Pindara-Private-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
20
trial(s) found.
NCT07165067
Advanced
Phase 1
Not yet recruiting
A Phase 1, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients With Solid Tumors. (
AP601-101
)
bispecific CD73/4-1BB antibody
Solid tumour
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NCT06953089
Advanced
Phase 2
Recruiting
A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors (
DB-1311-201
)
anti-B7H3 antibody-drug conjugate
anti-Trop2 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Solid tumour
NSW
2060 - North Sydney - Mater Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06669247
Haem
Phase 1
Recruiting
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
COSTIMM
)
bispecific CD38/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05957081
Advanced
Phase 1
Not yet recruiting
A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors (
MarkV-01
)
anti-PD-1 monoclonal antibody
anti-VISTA monoclonal antibody
Solid tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NCT05949684
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "
ELEMENT-MDS
" Trial
recombinant human ActRIIb fusion protein
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4217 - Benowa - Pindara Private Hospital
NCT05862012
Haem
Phase 1
Recruiting
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma (
ISB-2001-101
)
trispecific T-cell engager,BCMA/CD38-targeting
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05828589
Haem
Phase 1
Recruiting
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies (
CT-2023-CTN-05421-1--BGB-21447-101
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Follicular lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05756322
Haem
Phase 1
Recruiting
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias (
LBS-007-CT01
)
CDC7 inhibitor
Leukaemia
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05676931
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer (
EDGE-Lung
)
CD73 inhibitor
Docetaxel
Domvanalimab
Quemliclustat
Zimberelimab
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
cancer therapy
cancer therapy,CD73-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
taxane
Non-small cell lung cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
QLD
4217 - Benowa - Pindara Private Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05652855
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors (
MHB088C-CP001EN
)
anti-B7H3 antibody-drug conjugate
Solid tumour
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05642949
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors (
MHB036C-CP001EN
)
anti-Trop2 antibody-drug conjugate
Solid tumour
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05623020
Haem
Phase 3
Recruiting
MAGNETISMM-6
: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE OR ELRANATAMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NCT05462236
Advanced
Phase 2
Recruiting
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
NCT05458219
Advanced
Phase 1
Recruiting
A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI343A101
)
anti-CLDN18.2 antibody-drug conjugate
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
NCT05317416
Haem
Phase 3
Recruiting
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION (
MagnetisMM-7
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4217 - Benowa - Pindara Private Hospital
NA
NA
NCT05205109
Advanced
Phase 1
Recruiting
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (
ATG-037-001
)
CD73 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit (TERMINATED)
WA
6009 - Nedlands - One Clinical Research
NCT05150457
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (
BNA035-101
)
bispecific EGFR/4-1BB antibody
Solid tumour
NSW
2217 - Kogarah - St George Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
NCT05020236
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR (
MAGNETISMM-5
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04964518
Haem
Phase 1
Recruiting
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (
APG2575AU101
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Solid tumour
VIC
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
ACTRN12622000856718
Haem
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (
ISB-1442-101
)
bispecific CD38/CD47 antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Not yet recruiting (5)
Recruitment Country and State
QLD (20)
VIC (17)
NSW (13)
WA (8)
SA (6)
NZ (2)
TAS (1)
Phase
Phase 1 (10)
Phase 1 / Phase 2 (3)
Phase 2 (3)
Phase 3 (4)
Trial Type
Advanced (10)
Haem (10)
Cancer Therapy Class
PD-1/PD-L1
25%
BCMA
25%
CD38
25%
PD-1
20%
CD73
15%
Bcl2
15%
cereblon
15%
4-1BB
10%
B7H3
10%
Trop2
10%
DNA methyltransferase
10%
PD-L1
5%
VEGFA
5%
CD28
5%
VISTA
5%
CDC7
5%
TIGIT
5%
MNK
5%
CLDN18.2
5%
EGFR
5%
CD47
5%
Facility
4217 - Benowa - Pindara Private Hospital (20)
3066 - Epping - Northern Hospital (7)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
2500 - Wollongong - Wollongong Hospital (5)
3004 - Melbourne, Southbank - Alfred Health (5)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
3121 - Richmond - Epworth Freemasons Hospital (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (3)
4575 - Birtinya - Sunshine Coast University Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
3168 - Clayton - Monash Medical Centre (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
NA
2060 - North Sydney - Mater Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2217 - Kogarah - St George Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
6000 - Perth - Royal Perth Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Leukaemia
Myelodysplastic syndrome
Myeloproliferative neoplasm
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Follicular lymphoma
High-grade B-cell lymphoma
Lymphoid leukaemia
Lymphoma
Marginal zone lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy